Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany
Starting soon
Conditions studied: Haemophilia A
In brief
This study aims to generate structured patient preference evidence on prophylactic treatment options for haemophilia A for adults with and without inhibitors to support health technology assessment and benefit evaluation processes. The study will examine how individuals with haemophilia A evaluate trade-offs between treatment effectiveness, safety, and treatment administration characteristics when choosing between prophylactic therapies. Participants will repeatedly choose between hypothetical treatment profiles that differ in clinically relevant attributes and levels.
Key facts
- Study ID
- NCT07653139
- Run by
- Novo Nordisk A/S
- People needed
- 150
- Starts
- 2026-07-10
- Expected to finish
- 2026-10-26
- Last updated by the study team
- 2026-06-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- Participant has the mental capacity and sufficient German language proficiency to understand the study procedures and to complete the survey.
- Age above or equal to 18 years at the time of signing informed consent.
- Validated diagnose with haemophilia A, with and without inhibitors.
- Resident in Germany.
You may not qualify if…
- No provision of informed consent in this study.
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- Age below 18 years at the time of signing informed consent.
- Absence of a diagnosis of haemophilia A.
- No residence in Germany.
Where it is running
- Novo Nordisk Investigational Site — Mainz, Gonsenheim, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.